PDCD1 and non-small cell lung carcinoma: Anti-PD-1/PD-L1 therapy improves median overall survival in advanced NSCLC in both first- and second-line settings compared to standard cytotoxic chemotherapy, with durable responses seen in around 20% [3–6].